Navigation Links
Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
Date:6/2/2008

Phase 2 Study for NKTR-102 Will Target Newly-Identified K-Ras Mutated

Oncogene Population in Patients with Advanced Colorectal Cancer New Phase 2 Clinical Trials Will Evaluate NKTR-102 in Advanced Breast and

Ovarian Cancers

SAN CARLOS, Calif., June 2 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced an expanded Phase 2 development plan for NKTR-102 (PEG-irinotecan). The company will target newly-characterized colorectal cancer patients with K-Ras mutated gene status in its Phase 2 study in advanced colorectal cancer. In addition, NKTR-102 will be evaluated in Phase 2 trials in two new indications: platinum-refractory ovarian cancer and advanced breast cancer that is refractory to anthracycline and/or taxane-based therapies. These studies are expected to commence in the second half of 2008.

Recent data(2) presented at the 2008 American Society of Clinical Oncologists (ASCO) Annual Meeting shows colorectal cancer (CRC) patients with tumors that have K-Ras oncogene mutations (K-Ras mutant types) do not respond to EGFR-inhibitors, such as cetuximab. It is estimated that up to 45% of colorectal cancer cases have this mutated K-Ras gene. To target this newly- characterized K-Ras mutant patient population, Nektar will initiate a prospective study to evaluate the efficacy of NKTR-102 monotherapy in these patients. The primary endpoint of this randomized trial will be a clinically meaningful improvement in progression-free survival as compared to standard irinotecan monotherapy.

"With these recent clinical studies on K-Ras, there is no longer a clear standard of care for the second-line treatment of advanced colorectal cancer in patients with the K-Ras gene mut
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 31, 2015 Today, the National Association ... ) issued a report urging greater accountability by ... taken against websites illegally selling medications online. As ... Identification Program Progress Report for State and Federal ... of websites illegally distribute medications and avoid retribution. ...
(Date:7/31/2015)... 2015 According to a new market ... Dry Heat, Ethylene Oxide, Filtration, E-beam, Gamma), Services (Onsite & ... - Global Forecast to 2020", published by MarketsandMarkets, The Sterilization ... by 2020, at a CAGR of 7.6%.from 2015 to 2020. ... data T ables and 37 ...
(Date:7/31/2015)... 31, 2015  Semler Scientific, Inc. (Nasdaq: SMLR ... to healthcare insurers and physician groups, today reported financial ... "In the second quarter of 2015, ... growth of 54%, quarter over quarter revenue growth of ... base of FloChec® units of 18%," said Doug Murphy-Chutorian, ...
Breaking Medicine Technology:NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 2NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 3Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 2Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 3Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 4Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6
... 7, 2011 Boston Scientific Corporation (NYSE: BSX ... the Federal Circuit affirmed the decision of the U.S. District ... in a suit involving Johnson & Johnson to be invalid. ... Johnson alleged that Boston Scientific,s PROMUS® Everolimus-Eluting Coronary Stent System ...
... Healthpoint Biotherapeutics today announced that Travis E. Baugh, ... Executive Vice President, Strategic and Commercial Development, will ... products and its R&D pipeline at two upcoming ... 2:30 pm(EDT) on Thursday, June 9, 2011 during ...
Cached Medicine Technology:Boston Scientific Announces Favorable Appellate Court Ruling Affirming Invalidity of J&J Patents 2Boston Scientific Announces Favorable Appellate Court Ruling Affirming Invalidity of J&J Patents 3Healthpoint Biotherapeutics to Present at Upcoming Investment Conferences 2
(Date:8/1/2015)... ... 01, 2015 , ... On Tuesday, July 28th, Symantec released a security industry ... been behind the attack on Anthem Inc. which resulted in one of the largest ... attacks and spear phishing campaigns. , For Joe Caruso, founder and CEO/CTO ...
(Date:8/1/2015)... , ... August 01, 2015 , ... “ reTXT ” ... at the latest and coolest applications on the market for iOS, Android, and Windows. ... shared with viewers allows users to clarify, edit and delete any message including ones ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Ticket Down is a reputable source of ... the MGM Grand Garden Arena. Fans of every genre of music will have an ... 18th, the first day of the festival, the following artists will perform: Sam Smith, ...
(Date:7/31/2015)... ... ... Super Bowl 50 will emanate from Levi’s Stadium in Santa Clara, CA on Sunday, ... Bowl. In the two weeks that separate the conference championships and the Super Bowl, there ... game will mark the 50th time it has been held and the festivities will take ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... new industry players to know in predictive health analytics , Jvion continues ... technologies. The firm creates predictive software that targets patient and population level illness ...
Breaking Medicine News(10 mins):Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 3Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2
... United Kingdom: Many of the probotic health drinks are ... labels, say a team of microbiologists//. While established brands ... are advertised and marketed through the online medium seem ... do not contain the requisite amount of beneficial bacteria ...
... millions of people who suffer from chronic allergies to ... to develop Parkinson’s disease later in life. ... has shown that people who suffer from allergic rhinitis, ... a ‘permanent cold’, are probably at a greater risk ...
... ministry views the contamination of soft drinks with utmost seriousness//. ... note of the studies carried out by Centre for Science ... print and electronic media on Aug 2. The report of ... ,The ministry views "the contamination of soft drinks with utmost ...
... Researchers have determined the structure of DNA-modifying enzyme that ... a study published in the August 4 issue of ... School of Medicine have presented their findings on the ... DNA. The findings could help in developing antiviral ...
... The tests only report the presence of drugs and not the ... the drug mean it will affect their performance? // Probably not," ... ,"With cannabis, for instance, detection could mean the impairment ... fat cells for a month) and really has no effect on ...
... St. Louis have found that a high percentage of ... in contrast to claims that children are being overmedicated. ... are suffering from the disease and would benefit from ... found was somewhat surprising," says Richard D. Todd, M.D., ...
Cached Medicine News:Health News:Researchers Hint At The Probability Of A Link Between Rhinitis And Parkinson’ 2Health News:Researchers Hint At The Probability Of A Link Between Rhinitis And Parkinson’ 3Health News:Structure of DNA-modifying enzyme In Small Pox Determined 2Health News:Structure of DNA-modifying enzyme In Small Pox Determined 3Health News:Treatment For ADHD In Kids Inadequate 2Health News:Treatment For ADHD In Kids Inadequate 3
... The A5500 is an extremely accurate ... high frequency, low noise probe and fast ... application of the probe along the visual ... display, large 7 CRT monitor, built-in thermal ...
... most advanced IOL workstation. Accurate, efficient and ... be used with a variety of regressive, ... to the needs of the patient. Convenient ... a foot pedal for hands-free operation, audible ...
... unit with graphic display and IOL power ... units include firmware module with SRK II, ... All model DGH 5000e and DGH 5100e ... reducing the possibility of short readings. The ...
The UD-1000 incorporates the latest ultrasound technology for eyecare specialists. It is the ideal choice for your modern diagnostic laboratory. The UD-1000 combines a powerful B-sector scan system w...
Medicine Products: